• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for Commercializing the specialty product FIBROMUN

Oct 1, 2024 | 2024, Investors, Press Releases

more details

Philogen to attend the European Association of Nuclear Medicine (EANM) annual meeting on October 19-23, 2024

Sep 27, 2024 | 2024, Past Events

Andrea Galbiati is giving a presentation about Philochem’s FAP-targeted radioligand therapeutics on October 20 (session 604), entitled “Development of Multivalent OncoFAP Derivatives for the Tumor-Targeted Delivery of Theranostic Radionuclides”. Dr. Sebastian Oehler...

Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2024 (Price sensitive)

Sep 25, 2024 | 2024, Investors, Press Releases

more details

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2024 (Price sensitive) – Courtesy English Translation

Sep 25, 2024 | 2024, Investors, Press Releases

more details

2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry for Samuele Cazzamalli, Head of Chemistry at Philochem

Sep 4, 2024 | 2024, Past Events, Press Releases

Dr. Samuele Cazzamalli, Head of Chemistry at Philochem, will be awarded the 2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry. 2024_EFMC_Prize_for Young_Medicinal_Chemist

Philogen to attend the EFMC ISMC 2024 on September 4, 2024 in Rome

Jul 16, 2024 | 2024, Past Events, Scientific

Dr. Samuele Cazzamalli is giving a presentation entitled “DNA-Encoded Chemical Libraries for the Discovery of Highly Potent Tumor-Targeting Ligands and for the Development of Anti-Cancer Small Molecule Therapeutics”. Follow the link for more...
« Older Entries
Next Entries »

Recent Posts

  • Deposito del Verbale dell’Assemblea degli Azionisti
  • Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026
  • The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)
  • Philogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026
  • Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it